(Press-News.org) PHILADELPHIA — The simultaneous inhibition of two separate and seemingly unrelated pathways could potentially provide an effective treatment for women with triple-negative breast cancer, according to results of two studies published in the November issue of Cancer Discovery, a journal of the American Association for Cancer Research.
Triple-negative breast cancers do not express three common targets of breast cancer treatments: the estrogen receptor, progesterone receptor and HER2/neu. As a result, women with triple-negative breast cancer have few treatment options. In early-phase clinical studies, those women with triple-negative breast cancer with BRCA1 gene mutations had some clinical benefit from treatments with poly-ADP-ribose-polymerase (PARP) inhibitors. However, the activity of the PARP inhibitors is short-lived.
"We are in desperate need of new therapies for triple-negative breast cancer, which is a type of breast cancer that is very aggressive and occurs mostly in young females," said José Baselga, M.D., Ph.D., chief of the division of hematology and oncology at Massachusetts General Hospital Cancer Center in Boston.
In their study, Baselga; Yasir Ibrahim, Ph.D., a postdoctoral fellow at Vall D'Hebron Institute of Oncology in Barcelona, Spain; and Maurizio Scaltriti, Ph.D., faculty assistant and lab coordinator at Massachusetts General Hospital Cancer Center, hypothesized that inhibiting PI3-kinase, a key component of a signaling pathway frequently activated inappropriately in triple-negative breast cancer, would replicate the conditions present in BRCA-mutated breast cancers, thereby increasing sensitivity to PARP inhibitors.
They found that if PI3-kinase function was blocked in a BRCA-proficient triple-negative breast cancer cell line, DNA damage would occur due to BRCA protein downregulation, and that this resulted in activation of PARP to repair the damage.
"In a way, with PI3-kinase inhibitors, we are converting BRCA-proficient triple-negative breast cancer into BRCA-deficient breast cancer and, therefore, these cells become sensitive to PARP inhibition," Baselga said.
In the second study, Lewis C. Cantley, Ph.D.; Gerburg Wulf, M.D., Ph.D.; and colleagues used an endogenous mouse model of BRCA1-deficient breast cancer. They observed that mice with a BRCA1 mutation also had molecular indicators of strong activation of the PI3-kinase pathway, suggesting that the tumors might be vulnerable to PI3-kinase inhibitors.
When the mice were treated with a PI3-kinase inhibitor, tumor doubling was delayed from five to 26 days. Given that BRCA-mutated tumors are also known to respond to PARP inhibitors, the researchers combined the two medications and found that this delayed tumor doubling to more than 70 days.
"We saw in vivo synergy that led to dramatic prolongation of progression-free survival in these mice of more than two to three months, which in the life of a mouse is very long," said Wulf, staff physician in the division of hematology and oncology at Beth Israel Deaconess Medical Center. "This is an unusual observation that makes us hopeful that it is worthwhile to explore in an early-phase clinical trial."
Both studies received funding from Stand Up To Cancer Dream Team Translational Research Grants.
Cantley, who conducted the research while director of the cancer center at Beth Israel Deaconess Medical Center in Boston, and his colleagues have worked with Novartis and AstraZeneca, the two companies that manufacture the PI3-kinase inhibitor (BKM120) and the PARP inhibitor (Olaparib) to initiate a clinical trial combining the two drugs in humans.
Cantley said it is extremely unusual for two unapproved drugs to be combined in a cancer clinical trial, especially when the two drugs are produced by separate companies. Yet the preclinical results were sufficiently compelling to accelerate the initiation of this trial. The trial, led by Ursula Matulonis, M.D., director of medical gynecologic oncology at the Dana-Farber Cancer Institute in Boston, is now open and starting to enroll patients with triple-negative breast or ovarian cancer.
"This is truly an amazing story where essentially the same week that the paper is coming out showing an observation, the clinical trial is starting," Cantley said. "This type of bench-to-bedside process typically takes five to 10 years but was dramatically accelerated by the collaborative efforts of the Stand Up To Cancer-funded PI3-Kinase Dream Team."
###
Follow the AACR on Twitter: @aacr #aacr
Follow the AACR on Facebook: http://www.facebook.com/aacr.org
About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world's first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 17,000 attendees. In addition, the AACR publishes seven peer-reviewed scientific journals and a magazine for cancer survivors, patients and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the scientific partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer.
For more information about the AACR, visit www.AACR.org.
PI3-kinase and PARP inhibitor combo may offer new treatment option for triple-neg breast cancers
2012-11-12
ELSE PRESS RELEASES FROM THIS DATE:
UNC, Vanderbilt discover a new live vaccine approach for SARS and novel coronaviruses
2012-11-12
Rapid mutation has long been considered a key to viral adaptation to environmental change. But in the case of the coronavirus responsible for deadly severe acute respiratory syndrome (SARS), collaborating researchers at the University of North Carolina and Vanderbilt University have found that accelerating the rate of mutations cripples the virus's ability to cause disease in animals. In addition, they say this finding may allow scientists to explore a new option for creating safer live vaccines.
A collaborative study, published Nov. 11 in Nature Medicine, demonstrates ...
Bringing measuring accuracy to radical treatment
2012-11-12
An international team of scientists working at the Plasma Technology research unit at Ghent University, Belgium, has determined for the first time the absolute density of active substances called radicals found in a state of matter known as plasma, in a study about to be published in EPJ D. These findings could have important implications for medicine—for example, for stimulating tissue regeneration, or to induce a targeted antiseptic effect in vivo without affecting neighbouring tissues.
Qing Xiong and colleagues utilised laser fluorescence spectroscopy (LIF), a detection ...
Duke Medicine news -- Genome sequencing of Burkitt Lymphoma reveals unique mutation
2012-11-12
DURHAM, N.C. – In the first broad genetic landscape mapped of a Burkitt lymphoma tumor, scientists at Duke Medicine and their collaborators identified 70 mutations, including several that had not previously been associated with cancer and a new one that was unique to the disease.
Findings from the genetic sequencing of Burkitt lymphoma, an aggressive form of lymphoma, could be used to develop new drugs or aim existing therapies at mutations known to be susceptible. The researchers published their findings online Sunday, Nov. 11, 2012, in the journal Nature Genetics.
"This ...
News from Annals of Internal Medicine
2012-11-12
Philadelphia, November 12, 2012 – A new article being published early online in Annals of Internal Medicine describes the diagnosis and treatment protocol established in a Roanoke, Va. hospital to care for dozens of patients presenting with suspected fungal meningitis related to contaminated epidural spinal injections. This unprecedented surge of patients seeking care for a rare central nervous system (CNS) infection required physicians to react quickly with little data to guide treatment decisions. The authors suggest that the data collected from these cases may fill information ...
Genetic link between pancreatitis and alcohol consumption, says Pitt team
2012-11-12
PITTSBURGH, Nov. 12, 2012 – A new study published online today in Nature Genetics reveals a genetic link between chronic pancreatitis and alcohol consumption. Researchers from the University of Pittsburgh School of Medicine and more than 25 other health centers across the United States found a genetic variant on chromosome X near the claudin-2 gene (CLDN2) that predicts which men who are heavy drinkers are at high risk of developing chronic pancreatitis.
This finding enables doctors to identify people with early signs of pancreatitis or an attack of acute pancreatitis ...
Job stress and mental health problems contribute to higher rates of physician suicide
2012-11-12
ANN ARBOR, Mich. — Doctors who commit suicide appear to be under-treated for mental health problems, despite their seemingly good access to health care, a new University of Michigan study shows.
Although more physicians than non-physicians in the study had known mental health problems prior to suicide, this didn't translate into a higher rate of antidepressant use, according to the study, which appears in General Hospital Psychiatry and provides a deeper look at why physicians may have a higher-than-average suicide rate.
Major depression is a known risk factor for ...
Robots enable scar-free hysterectomies for some women
2012-11-12
AUGUSTA, Ga. – The precision and three-dimensional view provided by robots can enable essentially scar-free surgery for some women needing hysterectomies, physicians report.
The case report in the Journal of Minimal Access Surgery is of a 46-year-old physically fit female with a history of excessive bleeding and benign growths on her uterus. Her surgery was performed through a two inch-long incision in the belly button, the thinnest part of the abdomen, using the robotic arms in a "chopstick" fashion, said Dr. John R. Lue, Chief of the Medical College of Georgia Section ...
Desecrated ancient temple sheds light on early power struggles at Tel Beth-Shemesh
2012-11-12
Tel Aviv University researchers have uncovered a unique 11th century BCE sacred compound at the site of Tel Beth-Shemesh, an ancient village that resisted the aggressive expansion of neighboring Philistines. The newly discovered sacred complex is comprised of an elevated, massive circular stone structure and an intricately constructed building characterized by a row of three flat, large round stones. Co-directors of the dig Prof. Shlomo Bunimovitz and Dr. Zvi Lederman of TAU's Sonia and Marco Nadler Institute of Archaeology say that this temple complex is unparalleled, ...
FASEB urges biomedical research community to speak out against sequestration
2012-11-12
Bethesda, MD – The Federation of American Societies for Experimental Biology (FASEB) is rallying the biomedical research community to advocate against devastating funding cuts facing the nation's research agencies unless Congress acts before the end of the year. Under sequestration, the National Institutes of Health (NIH) could lose $2.8 billion and would fund 25 percent (2,300) fewer grants. The National Science Foundation (NSF) could be cut by nearly $600 million. More than 5,800 emails have been sent to Congress in response to a FASEB e-action alert urging individuals ...
National study shows protective eyewear reduces eye, head, and facial injuries
2012-11-12
PROVIDENCE, R.I. – A new study conducted by researchers at Hasbro Children's Hospital, the Center for Injury Research and Policy of The Research Institute at Nationwide Children's Hospital, Fairfax (VA) County Public Schools, and Boston Children's Hospital has found that high school field hockey players competing in states with mandated protective eyewear have significantly lower rates of head, eye, and facial injuries when compared to players who compete in states without protective eyewear mandates.
Each academic year, an estimated 63,000 girls participate in high ...